Chugai Ups Forecast On Star Performer Hemlibra
Roche affiliate substantially raises full-year forecast following double-digit sales and profit growth, mainly on the back of strength for hemophilia drug Hemlibra.
You may also be interested in...
Japanese firm unveils major restructuring of R&D sites in Japan through a new $1bn core lab set to open in early 2023 and the closure of two other long-established facilities.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.